ASCO Meeting 2021 Participation

**Oral Abstract Session**

*Symptoms and Survivorship*
Discussant: Tara B. Sanft, MD
Session Available: June 4; 9:00 AM

**Education Sessions**

*The Way of the Future: Personalizing Treatment Plans Through Technology*
Chair: Lajos Pusztai, MD, PhD
Session Available: June 4; 9:00 AM

*ASCO/American Association of Cancer Research (AACR) Joint Session: HER-2/Neu Alterations—Using Biology to Drive Therapeutic Options in Cancers of the Breast, Gut, and Beyond*
Speaker: Patricia LoRusso, DO
Broadcast: June 7; 11:30 AM

*Checkpoint Inhibitor–Based Therapies: New Immuno-Oncology Targets and Resistance Mechanisms*
Chair: Kurt A. Schalper, MD, PhD
Broadcast: June 5; 5:00 PM

**Panel Discussions**

*Novel Opportunities for Interdisciplinary Care and Teleconsults in the Era of Digital Health*
Speaker: Nadine Housri, MD
Session Available: June 4; 9:00 AM

*Treatment Conundrums in the Global Setting: The Critical Contribution of Molecular Testing to Cost-Effective Targeted Therapies*
Panelist: Anees B. Chagpar, MD, MPH, MBA, MSc, MA, FACS, FRCS, FASCO
Session Available: June 4; 9:00 AM
Characterization of the tumor immune microenvironment of triple negative breast cancer (TNBC) patients who self-identify as African American (AA) or non-African American (NonAA).  
Authors: Kim Blenman, Michal Marczyk, Tao Qing, Tess O’Meara, Vesal Yaghoobi, Vasiliki Pelekanou, Yalai Bai, Emily Reisenbichler, Xiaotong Li, Vignesh Gunasekharan, Eiman Y Ibrahim, David L. Rimm, Lajos Pusztai, Kimberly Cole  
Abstract: 564  
Session Available: June 4; 9:00 AM

Treatment Efficacy Score (TES), a continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between trial arms in the I-SPY 2 trial.  
Authors: Michal Marczyk, Anna Mrukwa, Christina Yau, Denise M. Wolf, Laura van ‘t Veer, Laura Esserman, William Fraser Symmans, Lajos Pusztai  
Abstract: 587  
Session Available: June 4; 9:00 AM

First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).  
Abstract: 2612  
Session Available: June 4; 9:00 AM

Dynamics of circulating tumor DNA in patients with advanced solid tumors treated with cediranib and olaparib.  
Authors: Yiduo Hu, Azeet Narayan, Julia Wolfe, Dennis Vu, Trinh Thi, Chaitanya Kantak, S. Percy Ivy, Joseph Paul Eder, Patricia LoRusso, Joseph W. Kim, Abhijit Patel  
Abstract: 3035  
Session Available: June 4; 9:00 AM
Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.
Authors: Ronac Mamtani, Jonathan E. Rosenberg, Thomas Powles, Guru P. Sonpavde, Yohann Loriot, Ignacio Duran, Jae-Lyun Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel Castellano, Srikala S. Sridhar, Helle Pappot, Begoña P. Valderrama, Howard Gurney, Jens Bedke, Michiel Simon Van Der Heijden, Chunzhang Wu, Zsolt Hepp, Caroline McKay, Daniel P. Petrylak
Abstract: 4539
Session Available: June 4; 9:00 AM

Gynecologic Cancer
Defective mismatch repair associated mutational signatures, a prognostic and predictive biomarker in endometrial cancer.
Authors: Yifan Emily Chang, Naomi N Adjei, Wafa Khadraoui, Gary Altwerger
Abstract: 5528
Session Available: June 4; 9:00 AM

Head & Neck Cancer
Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients.
Authors: Rebecca Forman, Aarti K. Bhatia, Barbara Burtness
Abstract: 6042
Session Available: June 4; 9:00 AM

Head & Neck Cancer
Quantitative immunofluorescence and mRNA analysis of immune-related biomarker groups in matched paired tumor samples from OPHELIA window study in head and neck squamous cell carcinoma (HN SCC).
Authors: Amanda Psyrri, Myrto Moutafi, Georgia-Angeli Koliou, George Papaxoinis, Niki Gavrielatou, Panagiota Economopoulou, Ioannis Kotsantis, Maria Gkotzamanidou, Maria Anastasiou, Dimitrios G. Pectasides, Aileen Fernandez, Vesal Yaghoobi, Saba Shafi, Ioannis Vathiotis, Thazin I Aung, Stavros Gkolfinopoulos, Periklis Foukas, George Fountzilas, David L. Rimm
Abstract: 6064
Session Available: June 4; 9:00 AM

Health Services Research and Quality Improvement
Accessibility of Telehealth services for cancer care at cancer hospital in the United States.
Authors: Victoria A. Marks, Walter R. Hsiang, James Nie, Waez Umer, Afash Haleem, Bayan Galal, Irene Pak, Dana Kim, Patrick Aloysius Kenney, Michael S. Leapman
Abstract: 6535
Session Available: June 4; 9:00 AM

Health Services Research and Quality Improvement
Access to cancer care for Medicaid patients at cancer hospitals in the United States.
Health Services Research and Quality Improvement

Post-intervention lung cancer screening compliance among internal medicine resident physicians at a primary care clinic in Hartford, Connecticut.

Authors: Michael S. Leapman, Michaela Ann Dinan, Saamir Pasha, Samuel L. Washington, Xiaomei Ma, Cary Philip Gross

Abstract: 6554
Session Available: June 4; 9:00 AM

Health Services Research and Quality Improvement

Mediators of racial disparity in the use of prostate MRI.

Authors: Nerea Lopetegui-Lia, Daniel Condit, Gian Carlo Castor Lima, Dimitrios Drekolias, Jasmin Hundal, Syed Imran Mustafa Jafri, James Vredenburg

Abstract: 6569
Session Available: June 4; 9:00 AM

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes.

Authors: Amer Methqal Zeidan, Namita Joshi, Hrishikesh Kale, Wei-Jhih Wang, Shelby Corman, Kala Hill, Tehseen Salimi, Robert S. Epstein

Abstract: 7043
Session Available: June 4; 9:00 AM

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis.

Authors: Jan Philipp Bewersdorf, Amar Sheth, Shaurey Vetsa, Alyssa Grimshaw, Smith Giri, Nikolai Alexandrovich Podoltsev, Lohith Gowda, Roni Tamari, Martin S. Tallman, Raajit Rampal, Amer Methqal Zeidan, Maximilian Stahl

Abstract: 7045
Session Available: June 4; 9:00 AM

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromes.

Authors: Amer Methqal Zeidan, Jacqueline Suen Garcia, Pierre Fenaux, Uwe Platzbecker, Yasushi Miyazaki, Zhi-Jian Xiao, Ying Zhou, Kiran Naqvi, Steve Kye, Guillermo Garcia-Manero

Abstract: TPS7054
Session Available: June 4; 9:00 AM
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

*Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.*


Abstract: 8563
Session Available: June 4; 9:00 AM

Lung Cancer—Non-Small Cell Metastatic

*Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase ½ and phase 2 (ALTA) trials.*


Abstract: 9071
Session Available: June 4; 9:00 AM

Lung Cancer—Non-Small Cell Metastatic

*Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).*

Authors: Karen L. Reckamp, Mary Weber Redman, Konstantin H. Dragnev, Liza C. Villaruz, Bryan A. Faller, Tareq Al Baghdadi, Susan Hines, Lu Qian, Katherine Minichiello, David R. Gandara, Roy S. Herbst, Karen Kelly

Abstract: 9075
Session Available: June 4; 9:00 AM

Sarcoma

*Recurrence and disease-specific survival after 10-year disease-free interval in patients with primary retroperitoneal liposarcoma: Implications for long-term surveillance.*


Abstract: 11546
Session Available: June 4; 9:00 AM
**Poster Discussion Sessions**

**Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology**

_A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results_


Abstract: 3015  
Session Available: June 4; 9:00 AM

**Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology**

_A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors_

Authors: Patricia LoRusso, Mrinal M. Gounder, Manish R. Patel, Noboru Yamamoto, Todd Michael Bauer, Scott Laurie, Rolf Grempler, Teffany Davenport, Junxian Geng, Maren Rohrbacher, Mehdi Lahmar

Abstract: 3016  
Session Available: June 4; 9:00 AM

**Gynecologic Cancer**

_A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)_

Authors: Dana M Roque, Stefania Bellone, Eric R. Siegel, Natalia Buza, Elena Bonazzoli, Adele Guglielmi, Luca Zammataro, Nupur Nagarkatti, Samir Zaidi, Jungsoo Lee, Peter E. Schwartz, Elena Ratner, Ludmil B. Alexandrov, Akiko Iwasaki, Yong Kong, Eric Song, Weilai Dong, Julia Andrea Elvin, Jungmin Choi, Alessandro Santin

Abstract: 5523  
Session Available: June 4; 9:00 AM

**Head & Neck Cancer**

_Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311)._

Authors: Robert L. Ferris, Yael Flamand, Gregory S. Weinstein, Shuli Li, Harry Quon, Ranee Mehra, Joaquin J. Garcia, Jolie Ringash, Jan S. Lewin, Umamaheswar Duvvuri, Bert W. O’Malley, Enver Ozer, Giovana R. Thomas, Wayne Koch, Michael Elliot Kupferman, Richard Bryan Bell, Nabil F. Saba, Miriam Lango, Lynne I. Wagner, Barbara Burtness

Abstract: 6010  
Session Available: June 4; 9:00 AM

**Lung Cancer—Non-Small Cell Metastatic**

_A phase II study of rucaparib in patients with high genomic LOH and/or BRCA ½ mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A)._
Abstract: 9024
Session Available: June 4; 9:00 AM